Full Press Release Details
HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences:
Event: Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Date: Wednesday, September 16, 2020
Presentation Time: 9:30 AM ET
Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 22, 2020
Presentation Time: 9:10 AM ET
A live webcast of each presentation will be accessible in the Investor Relations section of the Compugen website at www.cgen.com. Replays will also be available following each live event.
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is in a Phase 1 clinical study. The Company's therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. The Company's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Director, Investor Relations and Corporate Communications
Email: [email protected]
Tel: +972 (3) 765-8124
Investor Relations contact:
LifeSci Advisors, LLC
Email: [email protected]
Tel: +1 (646) 597-6989
Josephine Belluardo, Ph.D.
LifeSci Communications
Email: [email protected]
Tel: +1 (646) 751-4361
SOURCE Compugen Ltd.
21 %
more press release views with